VolitionRx (NYSE:VNRX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX) in a report released on Wednesday morning,Benzinga reports. They currently have a $5.00 price objective on the stock.

Several other research firms have also recently commented on VNRX. StockNews.com started coverage on shares of VolitionRx in a research note on Thursday, January 23rd. They set a “sell” rating on the stock. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Price Performance

NYSE:VNRX opened at $0.61 on Wednesday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The business has a fifty day moving average of $0.64 and a 200-day moving average of $0.66.

Insider Buying and Selling at VolitionRx

In related news, CEO Cameron John Reynolds acquired 139,811 shares of the business’s stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Guy Archibald Innes acquired 174,764 shares of VolitionRx stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, with a total value of $99,615.48. Following the completion of the purchase, the director now directly owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 358,266 shares of company stock valued at $204,212. Corporate insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC increased its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the quarter. Geode Capital Management LLC owned 0.79% of VolitionRx worth $439,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.